

**RECEIVED  
CENTRAL FAX CENTER**

**NOV 09 2006**

Attorney Docket No.: 5843.200-US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schülein et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

**AMENDMENT UNDER 37 C.F.R. 1.111**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed June 13, 2006, please amend the above-identified application as follows:

**Amendments to the claims** are reflected in the listing of claims, which begins on page 3 of this document.

**Remarks and arguments** begin on page 5 of this document.

**RECEIVED  
CENTRAL FAX CENTER**

NOV 09 2006

Attorney Docket No.: 5843.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schüleln et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner M. Rao, fax number (571) 273-8300.

Respectfully submitted,

Date: November 9, 2006

  
Julie Tabarovsky  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097